source
- STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?Biotech companies don’t hide or obfuscate strong data.STAT · 8h ago↗ source
- Tenax Therapeutics' heart failure drug TNX-103 misses primary endpoint in Phase 3, shares plunge 85%Tenax Therapeutics announced that its investigational heart failure drug TNX-103 failed to meet the primary efficacy endpoint in the Phase 3 LEVEL trial. The trial, which enrolled patients with pu…